HLA-G expression: immune privilege for tumour cells?

被引:31
作者
Cabestre, FA
Lefebvre, S
Moreau, P
Rouas-Freiss, N
Dausset, J
Carosella, ED
Paul, P
机构
[1] Hop St Louis, Ctr Hayem, Serv Rech Hematoimmunol, CEA,DRM,DSV, F-75475 Paris 10, France
[2] Fdn Jean Dausset, CEPH, F-75010 Paris, France
关键词
HLA-G; melanoma; immune tolerance; tumour immune escape;
D O I
10.1006/scbi.1998.0104
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The non-classical class I antigen HLA-G has been shown to play a role in foeto-maternal tolerance. It interacts with inhibitory receptors to down-regulate natural killer and T cell cytotoxic functions. We here report our investigations on HLA-G expression in melanoma cells and its implication in the induction of immune tolerance to tumours. We provide the first evidence that both malignant human melanoma cell lines and ex vivo biopsies can exhibit high levels of HLA-G transcription with differential HLA-G isoform. transcription and protein expression patterns. We further demonstrated that melanoma cells that express HLA-G inhibit NK cytolysis. We thus propose that HLA-G expression may impede the elimination of malignant cells by anti-tumour immune effector cells, constituting a newly described mechanism by which tumour cells may evade immunosurveillance.
引用
收藏
页码:27 / 36
页数:10
相关论文
共 53 条
[1]   HLA-G class I gene expression in normal and malignant hematopoietic cells [J].
Amiot, L ;
Onno, M ;
Drénou, B ;
Monvoisin, C ;
Fauchet, R .
HUMAN IMMUNOLOGY, 1998, 59 (08) :524-528
[2]  
Bakker ABH, 1998, J IMMUNOL, V160, P5239
[3]   IL-15 is produced by a subset of human melanomas, and is involved in the regulation of markers of melanoma progression through juxtacrine loops [J].
Barzegar, C ;
Meazza, R ;
Pereno, R ;
Pottin-Clemenceau, C ;
Scudeletti, M ;
Brouty-Boyé, D ;
Doucet, C ;
Taoufik, Y ;
Ritz, J ;
Musselli, C ;
Mishal, Z ;
Jasmin, C ;
Indiveri, F ;
Ferrini, S ;
Azzarone, B .
ONCOGENE, 1998, 16 (19) :2503-2512
[4]   Endothelial cells in chorionic fetal vessels of first trimester placenta express HLA-G [J].
Blaschitz, A ;
Lenfant, F ;
Mallet, V ;
Hartmann, M ;
Bensussan, A ;
Geraghty, DE ;
Le Bouteiller, P ;
Dohr, G .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1997, 27 (12) :3380-3388
[5]   Towards development of T-cell vaccines [J].
Bona, CA ;
Casares, S ;
Brumeanu, TD .
IMMUNOLOGY TODAY, 1998, 19 (03) :126-133
[6]   HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C [J].
Braud, VM ;
Allan, DSJ ;
O'Callaghan, CA ;
Söderström, K ;
D'Andrea, A ;
Ogg, GS ;
Lazetic, S ;
Young, NT ;
Bell, JI ;
Phillips, JH ;
Lanier, LL ;
McMichael, AJ .
NATURE, 1998, 391 (6669) :795-799
[7]  
CABESTRE FA, 1998, IN PRESS J REPROD IM
[8]  
Cantoni C, 1998, EUR J IMMUNOL, V28, P1980, DOI 10.1002/(SICI)1521-4141(199806)28:06<1980::AID-IMMU1980>3.0.CO
[9]  
2-F
[10]   Natural killer clones recognize specific soluble HLA class I molecules [J].
Carbone, E ;
Terrazzano, G ;
Colonna, M ;
Tuosto, L ;
Piccolella, E ;
Franksson, L ;
Palazzolo, G ;
PerezVillar, JJ ;
Fontana, S ;
Karre, K ;
Zappacosta, S .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1996, 26 (03) :683-689